Uri Geiger - 05 Jun 2026 Form 4 Insider Report for NeuroPace Inc (NPCE)

Reporting relationship: Director
Issuer ticker: NPCE
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 17:10:33 UTC
Prior SEC filing: 24 Mar 2026
Next SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Leah Akin, Attorney-in-Fact

Key filing fact

Uri Geiger filed Form 4 for NeuroPace Inc (NPCE) on 05 Jun 2026.

Key facts

This page summarizes Uri Geiger's Form 4 filing for NeuroPace Inc (NPCE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 17:10.

Change

Previous filing in this sequence was filed on 24 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001467361 Primary reporting owner

Geiger Uri

Relationship: Director
Address: C/O NEUROPACE, INC., 455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Signature: /s/ Leah Akin, Attorney-in-Fact
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NPCE transaction

Common Stock

Award

Transaction value
Shares: +2,890
Change %: +19%
Price: $0.000000^*
Shares after: 17,748
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1

NPCE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,432,948
Date: 05 Jun 2026
Ownership: See footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NPCE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,368
Change %
Price: $0.000000^*
Shares after: 5,368
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,368
Exercise price: $15.74
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.

Footnote F2

Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.

Footnote F3

The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.